Product R&D

R&D Strategy

Leveraging strong scientific capabilities and support from world-class academic resources, InnoDrug implements a multi-pronged R&D strategy across multiple dimensions. Our research primarily focuses on novel compounds from natural sources and their subsequent optimization and structural refinement. We continuously explore ways to enhance the performance of new drugs across different indications, and aim to earn patient and market recognition through innovative mechanisms of action and novel therapeutic targets.

Product Pipeline

InnoDrug advances three major product pipelines. Our 20 in-house discovered innovative drug candidates span Phase I/II clinical studies, IND-enabling, and preclinical research, ensuring a robust and sustainable portfolio to support future launches.

Cardiovascular & Cerebrovascular

Oncology

Metabolism & Inflammatory Immunology

No.	Therapeutic Area	Program / Candidate	Target	Indication	2024	2025	2026	2027	2028	2029	2030
1	Cardiovascular & Cerebrovascular	Leonurine Sulfate Tablets (SCM-198)	Nox4	Hyperlipidemia	Phase I	Phase II		Phase III		Launch
2	Cardiovascular & Cerebrovascular	ZYZ-451	SOD/CAT	Heart Failure	Preclinical			IND	Phase I	Phase II	Phase III
3	Cardiovascular & Cerebrovascular	INDL-001 (HDAC4)	HDAC4	Vascular Inflammation	Preclinical			IND	Phase I	Phase II	Phase III
4	Cardiovascular & Cerebrovascular	INDL-002 (JMJD3)	JMJD3	Vascular Injury	Preclinical			IND	Phase I	Phase II	Phase III
5	Cardiovascular & Cerebrovascular	INDL-006 AS (Fra1)	Fra1	Vascular Aging (Upstream Large Molecule)	Preclinical				IND	Phase I	Phase II
6	Cardiovascular & Cerebrovascular	INDL-005 (GATA-4)	GATA-4	Vascular Aging (Midstream Large Molecule)	Preclinical				IND	Phase I	Phase II
7	Cardiovascular & Cerebrovascular	INDL-005 (GATA-4)	GATA-4	Vascular Aging (Downstream Large Molecule)	Preclinical				IND	Phase I	Phase II
8	Cardiovascular & Cerebrovascular	INDL-010 (HDAC4/SMYD3 Double AS)	HDAC4/ SMYD3	Vascular Aging (Double AS)	Preclinical					IND	Phase I
9	Oncology	ZYZ-384	SMYD3	Hepatocellular Carcinoma	Preclinical		IND	Phase I	Phase II		Phase III
10	Oncology	ZYZ-410	HO-1	Non-Small Cell Lung Cancer	Preclinical				IND	Phase I	Phase II
11	Oncology	YL-B11	DDR1	Pancreatic Cancer (DDR1)	Preclinical				IND	Phase I	Phase II
12	Oncology	YL-B1102	Blocks DDR1, CTLA-4, and PD-L1; Activates CD28	ADC and Multi-Target Large-Molecule Antitumor Therapy (CTLA-4, PD-L1)	Preclinical				IND	Phase I	Phase II
13	Metabolism & Inflammatory Immunology	S-Propargyl-Cysteine Capsules (ZYZ-802)	CSE	Rheumatoid Arthritis	IND	Phase I	Phase II	Phase III		Launch
14	Metabolism & Inflammatory Immunology	Uncaria Alkaloid (Gou-Teng Alkaloid)	PI3K/Akt/ GSK3β Pathway	Insulin Resistance, Diabetes, and Related Complications	Preclinical				IND	Phase I	Phase II
15	Metabolism & Inflammatory Immunology	M2-lipo SCM-198	MMP-9	Ulcerative Colitis (Leonurine Alkaloid Nanoformulation)	Preclinical				IND	Phase I	Phase II
16	Metabolism & Inflammatory Immunology	ZYZ-488	MMP-9	Dysmenorrhea and Premature Ovarian Insufficiency	Preclinical				IND	Phase I	Phase II
17	Metabolism & Inflammatory Immunology	Leonurine Sulfate	Specific molecules (TNF-α, IL-6, MMP-2, MMP-9) and signaling pathways (VEGF pathway)	Endometriosis	Preclinical				IND	Phase I	Phase II
18	Metabolism & Inflammatory Immunology	Allyl Cysteine Capsules	Nrf2/NF-κB	Infectious Diarrhea	Preclinical				IND	Phase I	Phase II
19	Metabolism & Inflammatory Immunology	Leonurine Sulfate Gel	Simultaneously inhibits pro-inflammatory pathways (JAK-STAT, PI3K-Akt) and activates pro-repair pathways (mTOR, ERK)	Wound Healing	Preclinical		IND	Phase I	Phase II	Phase III
20	Metabolism & Inflammatory Immunology	S-Propargyl-Cysteine Gel	–	Diabetic Foot Wound Repair and Skin Regeneration	Preclinical		IND	Phase I	Phase II	Phase III

Product Patents

No.	Product	Patent Status
1	Leonurine Sulfate (SCM-198)	✅ Granted patents: 13 in China, 1 in the EU (plus 1 pending), 1 in Japan, and 1 PCT patent
2	S-Propargyl-Cysteine (ZYZ-802)	✅ Granted patents: 11 in China, 1 in the U.S., and 1 PCT patent; 2 applications pending
3	ZYZ-384	✅ 1 granted patent in China
4	ZYZ-451	✅ 2 granted patents in China
5	Uncaria Alkaloid (Gou-Teng Alkaloid)	✅ 1 granted patent in China
6	YL-B11	✅ 1 granted patent in China
7	YL-B1102	✅ 1 granted patent in China
8	HDAC4 Inhibitor (INDL-001)	✅ 2 patent applications pending
9	JMJD3 Inhibitor (INDL-002)	✅ 1 application filed in China; 2 applications pending
10	SMYD3 Inhibitor (INDL-003)	✅ 1 application filed in China; 2 applications pending
11	FRA-1 Inhibitor (INDL-004)	✅ 2 patent applications pending
12	GATA-4 Inhibitor (INDL-005)	✅ 2 patent applications in preparation